Anacor Pharmaceuticals Announces That GSK Has Discontinued Clinical Development of GSK2251052

Anacor Pharmaceuticals

announced today that its collaboration partner GlaxoSmithKline (GSK) has discontinued clinical development of GSK2251052. As previously disclosed, GSK halted the most recent clinical trials of GSK2251052 due to the identification of microbiological findings of resistance in a small number of patients in the Phase 2b trial for the treatment of complicated urinary tract infections (cUTI). Since then, GSK has conducted additional pre-clinical research and, after assessing various options, has elected to discontinue further development of GSK2251052 and return all rights to GSK2251052 to Anacor. Anacor and GSK are currently working together to transition GSK2251052 back to Anacor.